TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)

Tatsuya Ioka, Makoto Ueno, Hideki Ueno, Joon Oh Park, Heung Moon Chang, Naoki Sasahira, Masashi Kanai, Ik Joo Chung, Masafumi Ikeda, Shoji Nakamori, Nobumasa Mizuno, Yasushi Omuro, Taketo Yamaguchi, Hiroki Hara, Kazuya Sugimori, Junji Furuse, Hiroyuki Maguchi, Masayuki Furukawa, Kengo Fukuzawa, Jun Suk KimSeigo Yukisawa, Masahiro Takeuchi, Takuji Okusaka, Narikazu Boku, Ichinosuke Hyodo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: In our previous randomised phase 2 study for patients with gemcitabine-refractory advanced pancreatic cancer, S-1 plus leucovorin improved progression-free survival compared with S-1 alone. Here, we evaluated the efficacy of TAS-118 (S-1 plus leucovorin) versus S-1 in overall survival (OS). Patients and methods: This randomised, open-label, phase 3 study was conducted at 58 centres in Japan and Korea. Patients with metastatic pancreatic cancer that progressed during first-line gemcitabine-based chemotherapy or recurred during or after post-operative gemcitabine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40–60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40–60 mg plus leucovorin 25 mg, twice daily for 1 week in a 2-week cycle). The primary end-point was OS. Results: A total of 603 patients were randomised, and 300 and 301 patients received TAS-118 and S-1, respectively. There was no difference in OS between groups (median OS for TAS-118 versus S-1, 7.6 months versus 7.9 months; hazard ratio [HR], 0.98 [95% confidence interval (CI), 0.82–1.16]; P = 0.756). Progression-free survival was significantly longer with TAS-118 than S-1 (median, 3.9 months versus 2.8 months; HR, 0.80 [95% CI, 0.67–0.95]; P = 0.009). There were interactions between Japan and Korea (P = 0.004) and between unresectable and recurrent disease (P = 0.025) in OS. Incidence, profile and severity of adverse events were similar between groups. Conclusion: TAS-118 did not improve OS in patients with gemcitabine-refractory advanced pancreatic cancer compared to S-1. Further studies are needed to find patients who have benefit from adding leucovorin to S-1.

Original languageEnglish
Pages (from-to)78-88
Number of pages11
JournalEuropean Journal of Cancer
Volume106
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

gemcitabine
Leucovorin
Pancreatic Neoplasms
Survival
Korea
Disease-Free Survival
Japan
Confidence Intervals

Keywords

  • Fluorouracil
  • Leucovorin
  • Pancreatic cancer
  • S-1
  • Second-line chemotherapy
  • TAS-118

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer : a randomised, open-label, phase 3 study (GRAPE trial). / Ioka, Tatsuya; Ueno, Makoto; Ueno, Hideki; Park, Joon Oh; Chang, Heung Moon; Sasahira, Naoki; Kanai, Masashi; Chung, Ik Joo; Ikeda, Masafumi; Nakamori, Shoji; Mizuno, Nobumasa; Omuro, Yasushi; Yamaguchi, Taketo; Hara, Hiroki; Sugimori, Kazuya; Furuse, Junji; Maguchi, Hiroyuki; Furukawa, Masayuki; Fukuzawa, Kengo; Kim, Jun Suk; Yukisawa, Seigo; Takeuchi, Masahiro; Okusaka, Takuji; Boku, Narikazu; Hyodo, Ichinosuke.

In: European Journal of Cancer, Vol. 106, 01.01.2019, p. 78-88.

Research output: Contribution to journalArticle

Ioka, T, Ueno, M, Ueno, H, Park, JO, Chang, HM, Sasahira, N, Kanai, M, Chung, IJ, Ikeda, M, Nakamori, S, Mizuno, N, Omuro, Y, Yamaguchi, T, Hara, H, Sugimori, K, Furuse, J, Maguchi, H, Furukawa, M, Fukuzawa, K, Kim, JS, Yukisawa, S, Takeuchi, M, Okusaka, T, Boku, N & Hyodo, I 2019, 'TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)', European Journal of Cancer, vol. 106, pp. 78-88. https://doi.org/10.1016/j.ejca.2018.10.004
Ioka, Tatsuya ; Ueno, Makoto ; Ueno, Hideki ; Park, Joon Oh ; Chang, Heung Moon ; Sasahira, Naoki ; Kanai, Masashi ; Chung, Ik Joo ; Ikeda, Masafumi ; Nakamori, Shoji ; Mizuno, Nobumasa ; Omuro, Yasushi ; Yamaguchi, Taketo ; Hara, Hiroki ; Sugimori, Kazuya ; Furuse, Junji ; Maguchi, Hiroyuki ; Furukawa, Masayuki ; Fukuzawa, Kengo ; Kim, Jun Suk ; Yukisawa, Seigo ; Takeuchi, Masahiro ; Okusaka, Takuji ; Boku, Narikazu ; Hyodo, Ichinosuke. / TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer : a randomised, open-label, phase 3 study (GRAPE trial). In: European Journal of Cancer. 2019 ; Vol. 106. pp. 78-88.
@article{64ee244da0494f07a1bea627b2fdac52,
title = "TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial)",
abstract = "Background: In our previous randomised phase 2 study for patients with gemcitabine-refractory advanced pancreatic cancer, S-1 plus leucovorin improved progression-free survival compared with S-1 alone. Here, we evaluated the efficacy of TAS-118 (S-1 plus leucovorin) versus S-1 in overall survival (OS). Patients and methods: This randomised, open-label, phase 3 study was conducted at 58 centres in Japan and Korea. Patients with metastatic pancreatic cancer that progressed during first-line gemcitabine-based chemotherapy or recurred during or after post-operative gemcitabine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40–60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40–60 mg plus leucovorin 25 mg, twice daily for 1 week in a 2-week cycle). The primary end-point was OS. Results: A total of 603 patients were randomised, and 300 and 301 patients received TAS-118 and S-1, respectively. There was no difference in OS between groups (median OS for TAS-118 versus S-1, 7.6 months versus 7.9 months; hazard ratio [HR], 0.98 [95{\%} confidence interval (CI), 0.82–1.16]; P = 0.756). Progression-free survival was significantly longer with TAS-118 than S-1 (median, 3.9 months versus 2.8 months; HR, 0.80 [95{\%} CI, 0.67–0.95]; P = 0.009). There were interactions between Japan and Korea (P = 0.004) and between unresectable and recurrent disease (P = 0.025) in OS. Incidence, profile and severity of adverse events were similar between groups. Conclusion: TAS-118 did not improve OS in patients with gemcitabine-refractory advanced pancreatic cancer compared to S-1. Further studies are needed to find patients who have benefit from adding leucovorin to S-1.",
keywords = "Fluorouracil, Leucovorin, Pancreatic cancer, S-1, Second-line chemotherapy, TAS-118",
author = "Tatsuya Ioka and Makoto Ueno and Hideki Ueno and Park, {Joon Oh} and Chang, {Heung Moon} and Naoki Sasahira and Masashi Kanai and Chung, {Ik Joo} and Masafumi Ikeda and Shoji Nakamori and Nobumasa Mizuno and Yasushi Omuro and Taketo Yamaguchi and Hiroki Hara and Kazuya Sugimori and Junji Furuse and Hiroyuki Maguchi and Masayuki Furukawa and Kengo Fukuzawa and Kim, {Jun Suk} and Seigo Yukisawa and Masahiro Takeuchi and Takuji Okusaka and Narikazu Boku and Ichinosuke Hyodo",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ejca.2018.10.004",
language = "English",
volume = "106",
pages = "78--88",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer

T2 - a randomised, open-label, phase 3 study (GRAPE trial)

AU - Ioka, Tatsuya

AU - Ueno, Makoto

AU - Ueno, Hideki

AU - Park, Joon Oh

AU - Chang, Heung Moon

AU - Sasahira, Naoki

AU - Kanai, Masashi

AU - Chung, Ik Joo

AU - Ikeda, Masafumi

AU - Nakamori, Shoji

AU - Mizuno, Nobumasa

AU - Omuro, Yasushi

AU - Yamaguchi, Taketo

AU - Hara, Hiroki

AU - Sugimori, Kazuya

AU - Furuse, Junji

AU - Maguchi, Hiroyuki

AU - Furukawa, Masayuki

AU - Fukuzawa, Kengo

AU - Kim, Jun Suk

AU - Yukisawa, Seigo

AU - Takeuchi, Masahiro

AU - Okusaka, Takuji

AU - Boku, Narikazu

AU - Hyodo, Ichinosuke

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: In our previous randomised phase 2 study for patients with gemcitabine-refractory advanced pancreatic cancer, S-1 plus leucovorin improved progression-free survival compared with S-1 alone. Here, we evaluated the efficacy of TAS-118 (S-1 plus leucovorin) versus S-1 in overall survival (OS). Patients and methods: This randomised, open-label, phase 3 study was conducted at 58 centres in Japan and Korea. Patients with metastatic pancreatic cancer that progressed during first-line gemcitabine-based chemotherapy or recurred during or after post-operative gemcitabine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40–60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40–60 mg plus leucovorin 25 mg, twice daily for 1 week in a 2-week cycle). The primary end-point was OS. Results: A total of 603 patients were randomised, and 300 and 301 patients received TAS-118 and S-1, respectively. There was no difference in OS between groups (median OS for TAS-118 versus S-1, 7.6 months versus 7.9 months; hazard ratio [HR], 0.98 [95% confidence interval (CI), 0.82–1.16]; P = 0.756). Progression-free survival was significantly longer with TAS-118 than S-1 (median, 3.9 months versus 2.8 months; HR, 0.80 [95% CI, 0.67–0.95]; P = 0.009). There were interactions between Japan and Korea (P = 0.004) and between unresectable and recurrent disease (P = 0.025) in OS. Incidence, profile and severity of adverse events were similar between groups. Conclusion: TAS-118 did not improve OS in patients with gemcitabine-refractory advanced pancreatic cancer compared to S-1. Further studies are needed to find patients who have benefit from adding leucovorin to S-1.

AB - Background: In our previous randomised phase 2 study for patients with gemcitabine-refractory advanced pancreatic cancer, S-1 plus leucovorin improved progression-free survival compared with S-1 alone. Here, we evaluated the efficacy of TAS-118 (S-1 plus leucovorin) versus S-1 in overall survival (OS). Patients and methods: This randomised, open-label, phase 3 study was conducted at 58 centres in Japan and Korea. Patients with metastatic pancreatic cancer that progressed during first-line gemcitabine-based chemotherapy or recurred during or after post-operative gemcitabine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40–60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40–60 mg plus leucovorin 25 mg, twice daily for 1 week in a 2-week cycle). The primary end-point was OS. Results: A total of 603 patients were randomised, and 300 and 301 patients received TAS-118 and S-1, respectively. There was no difference in OS between groups (median OS for TAS-118 versus S-1, 7.6 months versus 7.9 months; hazard ratio [HR], 0.98 [95% confidence interval (CI), 0.82–1.16]; P = 0.756). Progression-free survival was significantly longer with TAS-118 than S-1 (median, 3.9 months versus 2.8 months; HR, 0.80 [95% CI, 0.67–0.95]; P = 0.009). There were interactions between Japan and Korea (P = 0.004) and between unresectable and recurrent disease (P = 0.025) in OS. Incidence, profile and severity of adverse events were similar between groups. Conclusion: TAS-118 did not improve OS in patients with gemcitabine-refractory advanced pancreatic cancer compared to S-1. Further studies are needed to find patients who have benefit from adding leucovorin to S-1.

KW - Fluorouracil

KW - Leucovorin

KW - Pancreatic cancer

KW - S-1

KW - Second-line chemotherapy

KW - TAS-118

UR - http://www.scopus.com/inward/record.url?scp=85056895259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056895259&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.10.004

DO - 10.1016/j.ejca.2018.10.004

M3 - Article

C2 - 30471651

AN - SCOPUS:85056895259

VL - 106

SP - 78

EP - 88

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -